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AbstrACt
Introduction Over 40% of global tuberculosis 
case notifications are diagnosed clinically without 
mycobacteriological confirmation. Standard diagnostic 
algorithms include ‘trial- of- antibiotics’—empirical 
antibiotic treatment given to mycobacteriology- negative 
individuals to treat infectious causes of symptoms 
other than tuberculosis, as a ‘rule- out’ diagnostic test 
for tuberculosis. Potentially 26.5 million such antibiotic 
courses/year are prescribed globally for the 5.3 million/
year mycobacteriology- negative patients, making trial- of- 
antibiotics the most common tuberculosis diagnostic, and 
a global- scale risk for antimicrobial resistance (AMR). Our 
systematic review found no randomised controlled trial 
(RCT) to support use of trial- of- antibiotic. The RCT aims 
to determine the diagnostic and clinical value and AMR 
consequences of trial- of- antibiotics.
Methods and analysis A three- arm, open- label, RCT 
randomising (1:1:1) Malawian adults (≥18 years) seeking 
primary care for cough into: (a) azithromycin 500 mg 
one time per day for 3 days or (b) amoxicillin 1 g three 
times per day for 5 days or (c) standard- of- care (no 
immediate antibiotic). We will perform mycobacteriology 
tests (microscopy, Xpert MTB/RIF (Mycobacterium 
tuberculosis/rifampicin) and Mycobacterium tuberculosis 
culture) at baseline. We will use audiocomputer- assisted 
self- interview to assess clinical improvement at day 
8. First primary outcome will be proportion of patients 
reporting day 8 improvement out of those with negative 
mycobacteriology (specificity). Second primary outcome 
will be day 29 incidence of a composite endpoint of either 
death or hospitalisation or missed tuberculosis diagnosis. 
To determine AMR impact we compare proportion of 
resistant nasopharyngeal Streptococcus pneumoniae 
isolates on day 29. 400 mycobacteriology- negative 
participants/arm will be required to detect a ≥10% 
absolute difference in diagnostic specificity with 80% 
power. We will estimate measures of effect by comparing 
outcomes in antibiotic arms (combined and individually) to 
standard- of- care.
Ethics and dissemination The study has been reviewed 
and approved by Malawi College of Medicine Research 
and Ethics Committee, London School of Hygiene & 
Tropical Medicine (LSHTM) Research Ethics Committee 
and Regional Committee for Health and Research Ethics 
– Norway, and Malawi Pharmacy, Medicines and Poisons 
Board. We will present abstracts at relevant conferences, 
and prepare a manuscript for publication in a peer- 
reviewed journal.
trial registration number The clinical trial is registered 
with  ClinicalTrials. gov, NCT03545373
IntroduCtIon
The high case- fatality rate for tuberculosis, 
the leading global infectious cause of death 
in adults1 with approximately 10 million 
cases and 1.6 million deaths in 2017,2 in 
part reflects suboptimal diagnostics.3–6 To 
complement this diagnostic gap, standard 
algorithms throughout the world include a 
‘trial- of- antibiotics’ (figure 1). This is a course 
of broad- spectrum antibiotics, with negligible 
strengths and limitations of this study
 ► To our knowledge this is the first randomised con-
trolled trial to address benefits and consequences 
of using antibiotics as an exclusion diagnostic for 
tuberculosis, a widely used practice that results in 
millions of antibiotic prescriptions/year.
 ► We will also contribute evidence on antimicrobial re-
sistance affecting common antimicrobials used for 
managing respiratory infections.
 ► The use of audio computer- assisted self- interview 
for assessing clinical response and adherence to 
antibiotic treatment which can be used in future 
studies.
 ► Acknowledged weaknesses include limited power 
to evaluate safety of deferred antibiotic treatment, 
conduct subgroup analysis by HIV status and the 
possibility that participants randomised to the 
standard- of- care arm may find alternative access to 
antibiotics therefore misclassifying exposure/inter-
vention status.
 o
n
 April 2, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from 
2 Divala TH, et al. BMJ Open 2020;10:e033999. doi:10.1136/bmjopen-2019-033999
Open access 
Figure 1 The position of trial- of- antibiotics in standard 
algorithms for diagnosis of tuberculosis in low- and middle- 
income countries (based on the 2018 WHO GLI model 
guidelines and as implemented in national guidelines, for 
example, Ghana, Malawi and South Africa). *The common 
clinical practice is that outpatients start antibiotics at the time 
of submitting sputum, to avoid the need for a third clinic visit 
to complete the algorithm. GLI,Global Laboratory Initiative; 
MTB, Mycobacterium tuberculosis; RIF, rifampicin; TB, 
tuberculosis.
Mycobacterium tuberculosis activity, given to patients with 
symptoms such as cough in order to ‘rule- out’ or ‘rule 
in’ tuberculosis.7–9 In clinical practice and most national 
guidelines (summarised in figure 1), patients who have 
negative sputum mycobacteriology and have responded to 
antibiotic treatment are considered tuberculosis- negative 
while those who remain symptomatic are deemed likely to 
have tuberculosis and undergo further evaluations poten-
tially leading on to receiving tuberculosis treatment.7–9
We estimate that 26.5 million courses of antibiotics 
are prescribed in the diagnosis of the 5.3 million smear- 
negative tuberculosis registrations recorded annually,10 
making antibiotics the most common diagnostic for 
tuberculosis.11 Our 26.5 million estimate assumes that 
for every one smear- negative tuberculosis case detected, 
five antibiotics courses are used: the first two courses 
being given to patients are ultimately registered as smear- 
negative tuberculosis, while the other three courses repre-
sent patients whose symptoms resolved without starting 
anti- tuberculosis treatment.4 12 This high frequency of 
prescription of important broad- spectrum antibiotics 
raises a global- scale risk for antimicrobial resistance 
(AMR) which like tuberculosis, is a major crisis, becoming 
in 2016 one of only four health topics ever to be discussed 
at the United Nations General Assembly.13–16
We performed a systematic literature review17 which 
demonstrated that, despite being in global and national 
guidelines for decades, trial- of- antibiotics has a limited 
supporting evidence base but with the available evidence 
suggesting poor diagnostic performance.18 None of the 
identified studies was an randomised controlled trial 
(RCT) and most of the observational studies were very 
small and not primarily designed to assess the benefits 
and consequences of trial- of- antibiotics. Pooled sensitivity 
and specificity of trial- of- antibiotics versus mycobacteri-
ology tests were below internationally defined minimum 
performance profiles for tuberculosis diagnostics.19
We hypothesise that use of antibiotics in the course of 
evaluating patients for tuberculosis has both benefits and 
risks that need to be weighed carefully to optimise patient 
and public health outcomes. We will address evidence 
gaps related to (a) accuracy, (b) antimicrobial resistance 
and (c) impact on clinical outcomes of trial- of- antibiotics 
by conducting an RCT (ACT- TB study) recruiting adult 
patients with cough presenting to health centres in Blan-
tyre, Malawi. To our knowledge this is the first randomised 
controlled trial to rigorously address these questions.
MEthods And AnAlysIs
study design
This is a three- arm individually randomised (1:1:1), open- 
label controlled clinical trial (RCT) investigating accu-
racy and broader clinical, and antimicrobial resistance 
impact of using trial- of- antibiotics to rule- out tubercu-
losis among adults presenting with cough at primary care 
centres in Malawi (figure 2). The trial is registered with 
ClinicalTrials. gov (online supplementary appendix 2). 
The full trial protocol is provided as online supplemen-
tary appendix 3.
study setting
We will screen adults aged at least 18 years presenting to 
Limbe and Ndirande health centres in Blantyre, Malawi. 
Blantyre has an estimated tuberculosis prevalence of 1014 
per 100 000 (95% CI: 486 to 1542), and an estimated 
adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6).20
Eligibility criteria
We will offer enrolment to patients who satisfy the 
following inclusion and exclusion criteria.
Inclusion criteria
 ► Ambulatory clinic attendees presenting with cough.
 ► Unwell for at least 14 days.
 ► Aged at least 18 years.
 ► Reside in Blantyre and willing to return to the same 
clinic for follow- up visits over the entire study period.
Exclusion criteria
 ► Self- reported allergy to study medications.
 ► WHO/Malawi National Tuberculosis Programme 
danger signs: respiratory rate >30/min, temperature 
>39°C, heart rate >120/minute, confused/agitated, 
respiratory distress, systolic blood pressure <90 mm 
Hg, inability to walk unassisted.
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Figure 2 Flow diagram for the clinical trial in Blantyre, 
Malawi. ART;antiretroviral therapy; LAM, lipoarabinomannan; 
NTP, Malawi National Tuberculosis Programme; TB, 
tuberculosis; VL, viral load.
 ► Treated with antibiotics other than co- trimoxazole 
prophylaxis within the past 14 days.
 ► Tuberculosis treatment or isoniazid preventive 
therapy within the last 6 months.
Interventions
We will randomise participants, in a ratio of 1:1:1, to the 
following arms:
 ► Arm 1 (azithromycin): Azithromycin 500 mg taken 
one time per day for 3 days from enrolment day.
 ► Arm 2 (amoxicillin): Amoxicillin 1 g taken three times 
per day for 5 days from enrolment day.
 ► Arm 3 (standard of care): No study antibiotic 
prescription.
rationale for interventions
Amoxicillin was chosen because it is the standard antibi-
otic used as first- line treatment and for trial- of- antibiotics 
in Malawi. However, amoxicillin may not demonstrate 
the best performance for trial- of- antibiotics because of 
increasing resistance, and a narrow coverage for aeti-
ology of community acquired pneumonia and ‘atyp-
ical’ organisms. We chose azithromycin to represent 
the optimal biological specificity of an oral regimen 
due to more complete coverage of atypical organ-
isms that cause community acquired pneumonia (eg, 
mycoplasma and chlamydia), and also the low resistance 
rates in Malawi where macrolides are rarely used. The 
dose for azithromycin is as recommended in the British 
National Formulary (BNF) as treatment for community- 
acquired pneumonia.21 The dose for amoxicillin is the 
BNF recommendation for severe infections but it is the 
recommended first- line established by the Department of 
Medicine at Queen Elizabeth Central Hospital (Blantyre, 
Malawi) based on local microbiology.
timing of interventions
The standard of care in Malawi defined by National Tuber-
culosis Programme guidelines for primary care patients 
presenting with cough who are otherwise well (no danger 
signs) is to take two sputum specimens for smear micros-
copy or Xpert and ask patients to return for results, 
typically 3 days to 1 week later (figure 1). The Malawi 
tuberculosis diagnostic algorithm recommends use of 
broad- spectrum antibiotics as trial- of- antibiotics after 
negative sputum tests are provided to patients who remain 
symptomatic. Therefore, the ideal population for rando-
misation for this study are patients on who already have 
negative results for smear microscopy or Xpert. However, 
that may have ethical challenges considering the implica-
tions of withholding treatment (if randomised to refer-
ence arm) from a symptomatic patient who, according 
to guidelines, should be given antibiotics. The first visit 
therefore was the most ideal time for randomisation and 
is in line with recommendations for test interval in inves-
tigations evaluating diagnostic tests with respect to the 
time interval between the index test (trial- of- antibiotics) 
and the reference test (mycobacteriology sputum sample 
collection). The timing also conforms to common clin-
ical practice of prescribing trial- of- antibiotics at the same 
time as sputum collection to reduce diagnostic delay. The 
design was discussed with the District Health Office and 
the National Tuberculosis Programme ahead of ethics 
submission.
Known drug reactions
Azithromycin and amoxicillin have a long registration 
history, have been widely used globally and are well toler-
ated. Rare side effects for azithromycin include nervous-
ness, dermatological reactions including Stevens- Johnson 
syndrome, anaphylaxis and prolonged QT interval. Rare 
side effects for amoxicillin are mental state changes, light-
headedness, photosensitivity and severe allergic reactions.
Concomitant medication and interaction with other therapies
We do not have any restrictions with respect to concomi-
tant medications apart from those listed in the exclusion 
criteria. We expect some participants to be on HIV antiret-
roviral drugs and some to subsequently start tuberculosis 
therapy. Important interactions therefore would be those 
between the product and HIV antiretroviral drugs. There 
is no moderate or major interaction between either azith-
romycin or amoxicillin with the classes of HIV antiretro-
viral drugs currently used in Malawi.
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Figure 3 Assessing the diagnostic value of a change in 
symptoms from baseline to day 8. MTB,Mycobacterium 
tuberculosis; RIF, rifampicin.
trial restrictions
We do not require participants to have any dietary 
restrictions. We will also accept co- administration with 
contraception. Azithromycin and amoxicillin are both 
considered safe in pregnancy, so we will include pregnant 
women should they be eligible.
Assessment of compliance
On Day 8, we will document self- reported compliance 
adherence of study products.
Withdraw of interventions
The investigator may also terminate a participant from 
study product if indicated by an adverse reaction. If a 
participant stops taking study product either voluntarily 
or by investigator decision, they will be encouraged 
to remain in follow- up and their data will form part of 
intention- to- treat analyses.
study outcomes
The clinical trial has two separately powered, and distinctly 
assessed primary outcomes, one for diagnostic evaluation 
(Primary outcome 1: Day 8) and the other for clinical 
impact (Primary outcome 2: Day 29) of the intervention. 
The following are descriptions of all study outcomes:
Primary outcome 1: specificity of day 8 symptom change versus 
mycobacteriology
The first primary outcome is the proportion of patients 
without tuberculosis (by sputum tests) who report 
improvement of their baseline illness when asked 7 days 
after randomisation (Day 8 study visit). This outcome can 
be thought of as diagnostic specificity if you take sputum 
test results as a reference standard and change in symptoms 
at Day 8 as the investigational test (figure 3). In this case 
the possible results of the investigational test are improve-
ment and no improvemet (no change or worsened) in 
response to the question: on Day 1, you reported that you 
were unwell; compared with that day, has your illness worsened, 
remained the same or improved?
As with all self- rated outcomes, social desirability 
bias (tendency of participants to answer questions in 
a manner that will be viewed favourably by healthcare 
worker), and interviewer bias (interviewers’ subconscious 
or conscious influencing subject response) may affect 
the outcome. To minimise these biasses in evaluation of 
improvement of baseline symptoms the interview will be 
conducted using audio computer- assisted self- interview 
(ACASI), a platform that allows patients to report their 
health state in private and directly into a database via an 
audio questionnaire administered by a tablet. The lack of 
human- to- human interaction will minimise interviewer, 
ascertainment and social desirability biasses. Another 
concern with open- label design is placebo- effect favouring 
those randomised to antibiotics over the standard of care 
arm that is however not addressed in our design.
We developed, piloted and optimised the ACASI ques-
tionnaire in the study target population and arrived at the 
question: on Day 1, you reported that you were unwell; compared 
with that day, has your illness worsened, remained the same or 
improved? Before proceeding to the self- interview, partici-
pants will be oriented using test questions until study staff 
are sure that they will be able to go through the interview 
on their own. We will term ACASI interview outcome as 
ACASI- test- negative if the participant reports improve-
ment or ACASI- test- positive if the participant reports no 
change or worsening (figure 3).
The mycobacteriology reference standard will be 
defined in participants with at least one valid sputum test 
result on Days 1 and 8 as sputum- test- positive if there is 
at least one positive of smear microscopy, Xpert MTB/
RIF or MTB culture; and as sputum- test- negative if none 
of the tests is positive. To minimise bias, the sputum tests 
will be performed by a high- quality research laboratory in 
the University of Malawi College of Medicine by staff with 
no access to participant treatment allocation information 
or symptom results.
The specificity of Day 8 symptom change (the index 
test measured using ACASI) against mycobacteriology 
tests (reference test) is defined as: proportion of sputum- 
test- negative who are ACASI- test- negative.
Primary outcome 2: clinical impact of trial-of-antibiotics
We will investigate the overall clinical impact of trial- of- 
antibiotics by comparing the Day 29 risk of any of death, 
hospitalisation and ‘missed tuberculosis’ (untreated 
mycobacteriological or radiological tuberculosis). All 
these events can lead to mortality and are potential conse-
quences of trial- of- antibiotics; therefore, grouping them 
as a composite endpoint appropriately represents the 
effect of the intervention because: (1) there are similari-
ties in the importance of each of the components, (2) the 
components occur with similar frequencies in the patient 
population and (3) the direction of effect is anticipated 
to be the same for all.22
The connection between trial- of- antibiotics and risk of 
hospitalisation and death assumes a protective effect of 
antibiotics. In patients presenting with chronic cough at 
primary care in high HIV prevalence settings, frequencies 
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of mortality and hospitalisation over a 2 months period 
are similar, ranging from 2% to 6%.23
We have included missed tuberculosis diagnosis in 
our composite clinical outcome because this too can 
lead to death. We are defining ‘missed tuberculosis’ as 
participants who meet standard mycobacteriological 
and radiological tuberculosis definitions but are incor-
rectly classified as tuberculosis- negative and not yet on 
tuberculosis treatment by Day 29. Clinical, radiological 
and microbiological evaluation for tuberculosis will be 
done at Day 8, Day 29, as well as day between these two 
for patients who report worsening symptoms.
Secondary outcome 1: impact of trial-of-antibiotics on 
antimicrobial resistance
We will use Streptococcus pneumoniae isolated from swabs of 
the nasopharynx as the indicator pathogen for AMR eval-
uation. An ecological niche for many bacterial species, the 
upper respiratory tract also presents a convenient window 
for investigating antimicrobial resistance. S. pneumoniae is 
the organism of choice not only for being an important 
cause of respiratory tract infections but also because it 
often colonises the upper respiratory tract, acquires resis-
tance readily and has well documented laboratory investi-
gation procedures in place.24
We will define AMR positive as having nasopha-
ryngeal isolates of S. pneumoniae that are resistant 
to any of the following commonly used antibiotics: 
ceftriaxone, amoxycillin, cefoxitin, azithromycin and 
erythromycin as determined using disc diffusion tech-
nique; and AMR negative as either (1) not isolating 
any S. pneumoniae or (2) isolating any S. pneumoniae 
that is not resistant to any of the assessed antibiotics. 
For each arm, and at both baseline and Day 29, we will 
report proportion of AMR positive participants. The 
study outcome will be the proportion of AMR positive 
participants at Day 29.
Secondary outcome 2: diagnostic value of trial-of-antibiotics in all 
patients including those without a valid sputum result
In this analysis, all will remain as described for primary 
outcome 1 except for the denominator, which will now 
include those without a valid sputum test result. The 
mycobacteriology reference standard for secondary 
outcome 2 will be defined as sputum test positive if at 
least one positive of smear microscopy, Xpert MTB/
RIF or MTB culture from samples collected on Days 1 
and 8. The reference test will be sputum- test- negative if 
none of the tests is positive and where there is no valid 
sputum test result available. The most likely reason 
for not having a valid sputum result will be inability to 
produce sputum, but other explanations will be: lost 
sample before laboratory analysis, an invalid laboratory 
reading or contamination. We have opted to analyse 
this population because in symptomatic adults of the 
study setting, failure to produce sputum can be as high 
as 13%.23
Secondary outcome 3: economic evaluation
The objective of the economic evaluation is to undertake 
a cost- utility analysis to estimate the incremental cost- 
effectiveness of trial- of- antibiotics using azithromycin 
and trial- of- antibiotics using amoxicillin in comparison to 
standard of care, and to each other. We will systematically 
compare costs and consequences associated with the inter-
ventions. We will perform a within trial comparison of the 
three treatment arms to estimate the incremental cost per 
quality- adjusted life year (QALY) gained for the azithro-
mycin or amoxicillin arm in comparison to standard of 
care. Costs will be estimated from the Malawian Ministry 
of Health perspective. Health outcomes will be quanti-
fied in QALYs, estimated from participants’ responses to 
the Chichewa version of the EQ- 5D- 3L, a health- related 
quality of life measure.25 26 We will adopt a time horizon 
matching the length of participant follow- up to achieve 
the within trial evaluation.
Exploratory outcomes
Our exploratory analyses will be comparisons between 
the azithromycin and amoxicillin arms for all our primary 
and secondary outcomes.
Planned subgroup analyses
We will perform analysis of primary outcomes stratified by 
HIV status and by antiretroviral therapy (ART) status as 
documented on enrolment day. This is important because 
the study site has high prevalence of HIV and associated 
bacterial infections which may be amenable to antibiotics 
used for trial- of- antibiotics.
study procedures
Figure 2 and table 1 presents the study time schedule 
including a summary of patient identification, baseline 
procedures and outcome ascertainment at Day 8 and Day 
29 follow- up visits.
Screening
Study staff will approach patients with symptoms of 
pulmonary tuberculosis (including cough of any dura-
tion, fever, weight loss and night sweats) with informa-
tion about the study and seek written informed consent 
(online supplementary appendix 4) from all patients 
who meet eligibility criteria. After consenting, a partici-
pant will be given a unique study identification number 
confirming enrolment.
Randomisation
Randomisation will be in the ratio 1:1:1 to the three 
arms of the trial, using block- randomisation with variable 
block sizes, and stratified by study site. An independent 
statistician will prepare the randomisation list using ralloc 
command in Stata software, then print each allocation 
alongside a randomisation number and seal in opaque 
envelopes. On confirming eligibility and consenting 
status a designated site staff will open the next available 
sequentially numbered randomisation envelopes and 
administer the allocated study arm.
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Table 1 Key study procedures over the study period
Time point
Study period
Enrolment Follow- up
Day 1 Day 8 Day 29
Enrolment
  Eligibility screen x
  Informed consent x
  Allocation x
Interventions
  Azithromycin x
  Amoxicillin x
  Standard of care x
Assessments
  Demographics x
  History of antibiotic use x x x
  History and examination* x x x
  Sputum collection† x x
  Urine for TB LAM test‡ x x
  Nasopharyngeal swab for 
AMR§
x x
  HIV test x
  Linking to routine care x x x
  ACASI¶ x
  Clinical events** x
  Update contact & address x x
*For symptomatic participants, Day 8 sputum mycobacteriology 
should be fast- tracked to inform care before they leave the clinic.
†Give sputum bottles at the end of Day 1 visit for submission on 
Day 8. Also collect sputum and perform mycobacteriology at any 
time of the study when clinically indicated.
‡Urine lipoarabinomannan for tuberculosis diagnosis (TB LAM).
§Nasopharyngeal swab for Streptococcus pneumoniae culture and 
sensitivity as a way of determining risk of antimicrobial resistance 
(AMR).
¶Audio computer- assisted self- interview (ACASI) for documenting 
change of symptoms on Day 8 versus Day 1.
**Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, 
new tuberculosis diagnosis, death, hospitalisation, missed 
tuberculosis diagnosis, HIV care loss to follow- up and tuberculosis 
care loss to follow- up.
Blinding
The study is not placebo controlled because of funding 
limitations, and so will not use blinding due to the nature 
of the study design. However, study team masking will be 
maintained with all study outcome assessment occurring 
without reference to randomisation arm.
Baseline procedures
At baseline, we will collect demographic data, clinical 
history, record vital signs, height and weight. Participants 
will be requested to provide two sputum samples for Xpert 
MTB/RIF and two more sputum samples the following 
morning for smear microscopy and MTB culture. We will 
also collect a urine sample for lipoarabamannan antigen 
detection (TB LAM); and a nasopharyngeal swab for 
pneumococcal culture and sensitivity testing. We will offer 
and perform HIV testing according to the national algo-
rithm, and link all who test positive to care. To minimise 
loss to follow- up, we will collect contact phone numbers, 
a physical address and geolocation information.
Participant follow-up
On Day 8, the first activity (ahead of any other interac-
tion with study staff) will be the ACASI. Other activities 
include providing results for Day 1 tuberculosis tests 
and linking those who test positive to care, collection of 
another sputum sample for smear microscopy and Myco-
bacterium tuberculosis (MTB) culture and management of 
ongoing symptoms and other illnesses. On visit Day 29, 
the final study visit, we will document participant vital 
status, hospitalisations and establish adherence to HIV 
and tuberculosis treatment. We will also collect nasopha-
ryngeal swab samples from all participants, and sputum 
from those with tuberculosis symptoms.
Participant retention
To minimise loss to follow- up, we will record geolocation 
information of participants’ place of residence using 
ePAL android application, a high- resolution mapping 
system validated in Blantyre. We will also record up to 
three contact phone numbers of the participant and 
their nominated friends and relatives. We will not replace 
participants who discontinue study participation or study 
treatment regardless of reason for withdrawal or discon-
tinuation or the time either of these occurs.
Data management
We will collect data using TeleForm (paper based system 
that uses optical character recognition) and Open Data 
Kit systems (ODK, an electronic data capture system 
installed on android devices). Data will be committed to 
a secure database located at Malawi- Liverpool Wellcome 
Trust within 2 days for TeleForm, and 7 days for ODK.
statistical approach
We will summarise the processes of recruitment including 
non- eligibility and reasons of exclusion in a CONSORT 
(Consolidated Standards of Reporting Trials) flow chart. 
We will describe the study participants by their baseline 
characteristics, by arm. We will perform analyses of all our 
outcomes based on an intention- to- treat analysis (using 
the arm patient was randomised to). Analysis for primary 
outcome 1 will be restricted to participants with a valid 
sputum test result. We will report measures of effect from 
the following comparisons: (i) azithromycin or amox-
icillin (combined) versus standard of care, (ii) azithro-
mycin versus standard of care and (iii) amoxicillin versus 
standard of care.
We will use a generalised linear model (GLM) with 
identity link to estimate risks differences and the GLM 
with log link to estimate risk ratios for the three compari-
sons, adjusting for study site. For each comparison, we will 
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Table 2A Sample size estimation for the diagnostic impact 
outcome comparing a combination of two antibiotic arms to 
standard of care arm (2:1 comparison)
Power (X2 
difference between 
independent 
proportions)
Effect size (50% SoC 
vs 60% amoxycillin 
or azithromycin)
Effective 
sample per 
arm (sputum 
negative 
participants 
needed)
0.80 0.10 290
0.85 0.10 332
0.90 0.10 388
Highlighted entries indicates target power and respective sample 
size estimates based on knowledge of TB risk, ability to produce 
and submit sputum and loss to follow- up.
Stata code: power two proportions 0.5 and 0.6, test (χ2), power 
(0.80), n ratio (2).
SoC, standard of care; TB, tuberculosis.
Table 2B Sample size estimation for the diagnostic 
impact outcome one antibiotic arm to standard of care arm 
(pairwise comparison)
Power (X2 
difference between 
independent 
proportions)
Effect size (50% SoC 
vs 60% amoxycillin 
or azithromycin)
Effective 
sample per 
arm (sputum 
negative 
participants 
needed)
0.80 0.10 388
0.85 0.10 443
0.90 0.10 519
Highlighted entries indicates target power and respective sample 
size estimates based on knowledge of TB risk, ability to produce 
and submit sputum, and loss to follow- up.
Stata code: power two proportions 0.5 and 0.6, test (χ2), power 
(0.80), n ratio (1).
SoC, standard of care; TB, tuberculosis.
report 95% CIs and p values from the likelihood test. If 
outcomes are rare, or the GLM model does not converge, 
we will use logistic regression to estimate the treatment 
effect using an OR. We will not perform adjustments for 
multiple comparisons but will report all effect sizes with 
their 95% CIs and p values to facilitate appropriate inter-
pretation of our results.
We will perform data cleaning and analysis using Stata 
release 15 (StataCorp, College Station, Texas, USA). 
The statistical approach will be expanded in a detailed 
statistical analysis plan, which will be finalised before 
unblinding the study data.
sample size and power
We performed power and sample size estimations for 
the diagnostic impact, clinical impact and AMR impact 
outcomes as described below. Our sample size estima-
tions are based on planned analysis that will use χ2 test for 
comparing two independent proportions.
Diagnostic impact outcome
We assume that at Day 8, change in well- being from 
baseline state in trial- of- antibiotics (azithromycin or 
amoxicillin) arms will correctly classify 60% of all 
mycobacteriology- negative participants (ie, 60% spec-
ificity of Day 8 symptom change in trial- of- antibiotics 
arms).12 We wanted to estimate a sample size that would 
provide a discriminatory power of 80% at a two- sided 
significance level of 5%, to detect at least 10% differ-
ence in specificity (ie, ≤50% specificity of Day 8 symptom 
change in standard of care arm).
sample size for a combination of two antibiotic arms against 
standard of care arm
The sample size estimates along with assumptions for 
this comparison are shown in the table 2A. To achieve 
the desired 80% discriminatory power, we will need to 
recruit at least 290 sputum- test- negative participants per 
arm. Accounting for TB prevalence, ability to produce 
and submit sputum, and loss to follow- up increases the 
sample to 453 per arm or 1359 for the whole study.
sample size for one antibiotic arm against standard of care 
arm
The sample size estimates along with assumptions for 
this comparison are shown in the table 2B. To achieve 
the desired 80% discriminatory power, we will need to 
recruit at least 388 sputum- test- negative participants per 
arm. Accounting for TB prevalence, ability to produce 
and submit sputum, and loss to follow- up increases the 
sample to 606 per arm or 1819 for the whole study (The 
ethics approved protocol uses an older calculation that 
yields 625 per arm and 1875 for whole study).
Power for clinical impact outcome
For the clinical impact of trial- of- antibiotics outcome, we 
assume a 4% baseline risk of composite outcome, and a 
loss to follow- up of 10% by Day 29. Using the sample size 
of 625 participants per arm (obtained in table 2B), and a 
type I alpha of 5%, we will be able to detect the difference 
between arms with 80% power, if the risk in the interven-
tion arm is twice that of the standard of care arm. This 
estimate is applicable to all comparisons shown in section 
3.
Power for AMR outcome
Study arms will be compared based proportion of partic-
ipants with resistant S. pneumoniae on Day 29. We assume 
that 45% of Day 29 nasopharyngeal swabs will success-
fully grow S. pneumoniae, and that 10% of the isolates will 
meet the definition of resistance (described earlier under 
outcomes), and that 10% will be lost to follow- up by Day 
29. Therefore, on Day 29, the standard of care arm (of 
625 participants) will have 253 S. pneumoniae isolates, 25 
of which would meet the definition of resistance. This 
translates into a 4% (25/625) risk of AMR positive cases 
in the standard of care arm. To detect a two- fold change 
in odds of Day 29 AMR risk with at least 80% power, using 
Pearson's χ2 test, at 0.05 alpha, we will need at least 431 
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and 553 participants per arm for the 2:1 and pairwise 
comparisons, respectively.
Monitoring and oversight
The trial will be monitored by the Research Support 
Centre Clinical Trials Unit of the University of Malawi 
College of Medicine. An independent Data and Safety 
Monitoring Board (DSMB), and a Trial Steering 
Committee have been set up and meet bi- annually.
trial closure
We will consider the trial closed after completing follow- up 
of the last enrolled participant, and on recording all 
mycobacteriology laboratory reports. Antimicrobial resis-
tance laboratory work will continue beyond trial closure. 
The trial may be terminated early by the Trial Steering 
Committee on recommendation of the DSMB. The 
halting rule for a trial arm is an unacceptable high level 
of deaths assessed using an alpha determined at the first 
DSMB meeting.
PAtIEnt And PublIC InvolvEMEnt
Patients were involved in the design of the study espe-
cially the ACASI used for collecting primary outcome 
data. Health workers were involved in the design of study 
visits and patient flow.
dIsCussIon
The ACT- TB study will investigate the benefits and 
consequences of ‘trial- of- antibiotics,’ a widely promoted 
approach to many patients with suspected tuberculosis in 
low- and middle- income countries without solid evidence 
base. To our knowledge, ACT- TB study is the first RCT 
of this kind. Results of our trial will add to the evidence- 
base regarding routine diagnosis of tuberculosis in low- 
and middle- income countries and strengthen our fight 
against AMR. Both tuberculosis and AMR are diseases of 
major importance globally, with tuberculosis causing an 
estimated 1.6 million deaths in 2017 and AMR projected 
to cause 10 million deaths per year by 2050.2 27
Choice of study interventions
We have chosen amoxicillin because it is the first- line 
treatment for outpatient management of pneumonia in 
Malawi and is commonly used for trial- of- antibiotics. It also 
provides data of immediate programmatic relevance and 
a starting point to investigate exacerbation of pre- existing 
AMR pressure. However, amoxicillin may not demon-
strate the full benefits for trial- of- antibiotics because 
of organisms with intrinsic (‘atypicals’) or acquired 
(common in gram- negative organisms, and Staphylococcus 
aureus) penicillin resistance.28 Oral antibiotics that may 
provide the better diagnostic discrimination for bacte-
rial versus mycobacterial causes of cough are macrolides, 
such as azithromycin, because of better intrinsic coverage 
of ‘atypical’ intracellular organisms such as mycoplasma 
species that cause community acquired pneumonia,29–31 
and low levels of acquired macrolide- resistance in bacte-
rial isolates in Malawi.28
ACAsI for post-treatment improvement assessment
Our systematic review18 did not identify a consistent defi-
nition of tuberculosis or no tuberculosis based on trial- 
of- antibiotics. A definition of clinical change following 
antibiotic treatment is necessary for the trial- of- antibiotics 
as this determines who get categorised as well or 
tuberculosis- positive. Approaches that ranged from self- 
reported improvement to a combination of clinical and 
radiological assessments are likely to be highly subjective 
and prone to bias, as well as being a potentially avoidable 
source of heterogeneity between studies. In this study, we 
hope to address these biasses (particularly, inter- observer 
variability, and patient/interviewer reporting or ascer-
tainment biasses) by using self- rated change of illness (on 
Day 8) recorded using a self- completed questionnaire, 
the ACASI (described under outcomes). The ACASI 
questionnaire, the delivery platform and the resulting 
data management can all be replicated in future studies, 
creating potential for more standardisation in assessment 
of clinical response to treatment.
Potential clinical impact of antibiotics
In areas with high HIV prevalence, empirical antibiotics 
during tuberculosis investigations could be life- saving: 
mortality immediately before and after tuberculosis diag-
nosis is high,3 32 and is often secondary to severe bacte-
rial infections.32–34 The leading aetiologies of infection 
and death on tuberculosis treatment as well as among 
outpatients with tuberculosis- like symptoms are S. pneu-
moniae and non- typhoidal salmonellae: both can present 
with cough (primary cause) or as comorbidities (super- 
infections) in patients presenting with active Mycobacte-
rium tuberculosis disease.32–34 If effective treatment of this 
type of life- threatening primary/super- infections reduces 
mortality during the diagnostic workup of suspected 
tuberculosis in people living with HIV, then empirical use 
of broad- spectrum antibiotics would be indicated for this 
purpose alone, irrespective of any diagnostic contribu-
tion to tuberculosis treatment decisions. In this context, 
azithromycin may be the most effective arm, as salmo-
nella infections are highly sensitive to azithromycin, but 
not to amoxicillin.28
AMr and trial-of-antibiotics
Antimicrobial resistance relating to antibiotic use 
during evaluation for suspected tuberculosis has not 
been investigated before. Previous work has shown that 
empirical antibiotics can drive rapid emergence of anti-
microbial resistance.35 36 Co- trimoxazole prophylaxis for 
HIV- positive patients, introduced in 2005, was followed 
by near- universal resistance in bloodstream infections 
by 2010.37 Mass drug administration of azithromycin 
for trachoma control initially reduces nasopharyngeal 
carriage of S. pneumoniae, but with increased macrolide- 
resistance 6 months later.38 39
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In this study we have the opportunity to assess the extent 
to which brief exposure drives antimicrobial resistance 
during diagnostic workup for tuberculosis. An ecological 
niche for many bacterial species, the upper respiratory 
tract also presents a convenient sampling opportunity for 
investigating antimicrobial resistance.40 S. pneumoniae is 
the organism of choice not only for being an important 
cause of respiratory tract infections but also because it 
often colonises the upper respiratory tract, acquires resis-
tance readily and has well documented laboratory investi-
gation procedures in place.24 As exploratory analyses, we 
will also assess nasopharygeal colonisation and antimicro-
bial resistance in relation to tuberculosis treatment and 
HIV status.
Important subgroups
Clinical response to trial- of- antibiotics is possible and 
indeed well- described in patients with bacteriologically 
confirmed tuberculosis (ie, false- negatives/low sensitivity 
from the perspective of tuberculosis diagnosis) may relate 
to multiple super- infections.4 33 As such, this phenom-
enon may vary by HIV status, since multiple concurrent 
infections are a hallmark of advanced HIV immunosup-
pression, and are most commonly reported in patients 
with suspected tuberculosis in the pre- ART era. In 2015, 
in Malawi, 45% of adults who presented to primary care 
with prolonged cough (≥2 weeks) were HIV- positive, of 
whom only~20% started tuberculosis treatment on the 
basis of positive mycobacteriology.23 As such, the bene-
fits and consequences of trial- of- antibiotics may vary by 
HIV status and ART coverage, and by subsequent tuber-
culosis treatment decisions. We will, therefore, include 
a prespecified subanalysis of trial outcomes stratified by 
HIV and ART status.
limitations
The study has several limitations. First, we did not use a 
placebo- control arm. Second, the study is not adequately 
powered to evaluate safety of deferred antibiotic treat-
ment or conduct subgroup analyses of outcomes by 
HIV status, both of which are important evidence gaps. 
Other limitations include the possibility that partici-
pants randomised to the standard- of- care arm may find 
alternative access to antibiotics therefore misclassifying 
exposure/intervention status. There is also a possibility 
of misclassifying active tuberculosis status because of the 
suboptimal nature of the available tests.
EthICs And dIssEMInAtIon
The study has been reviewed and approved by the 
University of Malawi College of Medicine Research and 
Ethics Committee (COMREC; registration number 
P.04/18/2381), the London School of Hygiene & Trop-
ical Medicine Research Ethics Committee (LSHTM EC; 
registration number 15232) and Regional Committee 
for Health and Research Ethics, NTNU- Midt, Norway 
(REK nord; registration number 208/1964). Regulatory 
approval has been granted by the Malawi Pharmacy, 
Medicines and Poisons Board (PMPB; registration 
number CTRC/III/14062018102). We will present any 
future protocol modifications to these bodies before 
implementing. We will submit results for publication in 
a peer- reviewed journal. We will submit abstracts to rele-
vant national and international conferences. This work 
will also form part of a PhD thesis for THD, which he will 
submit to the LSHTM. This study will follow the standards 
set by CONSORT guidelines.
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